Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Core Insights - The FDA has granted Fast Track Designation to Oncolytics Biotech's pelareorep for treating KRAS-mutant MSS metastatic colorectal cancer, indicating its potential as an immunotherapeutic platform in gastrointestinal cancers [1][2][3] Clinical Data - Pelareorep-based therapy shows a 33% objective response rate (ORR), significantly higher than the approximately 10% ORR with standard-of-care (SOC) [2] - The median progression-free survival (PFS) for pelareorep is 16.6 months, compared to 5.7 months with SOC, and the median overall survival (OS) is 27 months, compared to 11.2 months with SOC [2] Market Potential - There are approximately 2 million new colorectal cancer cases globally each year, with a total addressable market of $3-5 billion for the second-line KRAS-mutant MSS mCRC subgroup [2] Future Plans - The company plans to initiate a controlled clinical study comparing SOC alone versus SOC plus pelareorep, with the first clinical site expected to be activated in March 2026 and interim data anticipated by year-end [1][2] Regulatory Benefits - Fast Track Designation allows for more frequent communication with the FDA, potentially leading to Accelerated Approval and Priority Review if criteria are met [3]